Hikma Pharmaceuticals (DIFX:HIK) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DIFX:HIK Hikma Pharmaceuticals PLC DIFX:HIK
79 GF Score
Price $10.23
GF Value $14.00
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

DIFX:HIK vs ZTS, UTHR, VTRS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hikma Pharmaceuticals Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Short Interest falls into.


DIFX:HIK
79GF Score
Hikma Pharmaceuticals PLC DIFX:HIK
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hikma Pharmaceuticals (DIFX:HIK) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $10.23 is trading 26.9% below its estimated GF Value™ of $14.00.

Key valuation signals for DIFX:HIK:

  • Short Interest:
  • GF Value™: $14.00 vs. price of $10.23 (26.9% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the DIFX:HIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
79GF Score

Get the complete analysis for DIFX:HIK

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.23
Price
$14.00
GF Value